Image source: Shutterstock
Highlights
MVF receives BUY/OUTPERFORM ratings from several brokers including Ord Minnett, Bell Potter, and Jefferies.
Analysts have set target prices showing up to 95% upside potential from current levels.
The company is facing reputational risk after an incident at its Clayton laboratory, prompting internal reviews and process upgrades.
CEO Michael Knaap resigns, with CFO Malik Jainudeen stepping in as Acting CEO.
Monash IVF Group Ltd (ASX:MVF), an Australian reproductive healthcare company, continues to attract positive sentiment from market analysts. Despite recent operational and leadership challenges, the company has maintained a consensus BUY recommendation, with analysts forecasting significant upside for its share price.
Broker Endorsements Signal Confidence
Broker firms have reiterated positive stances:
-
Ord Minnett's analyst Tom Godfrey maintains a BUY rating with a target price of AUD 0.95, reflecting a 42.86% upside.
-
Bell Potter Securities (Institutional), via Martyn M. Jacobs, has a BUY call and projects the price to hit AUD 1.15, indicating a 72.93% gain.
-
Jefferies analyst David A. Stanton also issues a BUY recommendation, with a price target of AUD 1.05, suggesting a 57.89% increase.
-
Macquarie Research and Wilsons remain optimistic with OUTPERFORM and OVERWEIGHT calls respectively, and price targets going as high as AUD 1.30 and AUD 1.25—representing nearly 95% and 88% growth potential.
Incident at Clayton Facility Spurs Action
On June 5th, Monash IVF reported an incident at its Clayton laboratory, where a patient’s embryo was incorrectly transferred to the wrong individual—contrary to established treatment protocols. The company extended apologies to the affected couple and initiated an internal investigation.
In parallel, the scope of an existing independent review, led by Fiona McLeod AO SC, has been expanded to include this incident. This follows a similar review of an unrelated Brisbane incident earlier this year. Monash IVF has committed to transparency and will share findings in due course.
The company is also implementing additional interim safeguards that exceed standard practice, including enhanced verification protocols and patient confirmation steps, alongside its rollout of electronic witness systems across facilities.
CEO Resignation and Interim Leadership
In a separate development, Chief Executive Officer and Managing Director Michael Knaap has resigned, also stepping down from his role as a director of Monash IVF Group. The board expressed gratitude for Knaap’s leadership since 2019, a tenure marked by notable growth and transformation.
In the interim, Chief Financial Officer and Company Secretary Malik Jainudeen has been appointed as Acting CEO, ensuring continuity as the board commences its search for a permanent successor.
According to comapny's website, the company has a legacy of more than five decades and delivered over 50,000 babies.






Please wait processing your request...